Cerivastatin sodium NEW
| Price | $138 |
| Package | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-06-21 |
Product Details
| Product Name: Cerivastatin sodium | CAS No.: 143201-11-0 |
| Purity: 99.67% | Supply Ability: 10g |
| Release date: 2025/06/21 |
Product Introduction
Bioactivity
| Name | Cerivastatin sodium |
| Description | Cerivastatin sodium (BAY W 6228 sodium) is an orally active and highly potent HMG-CoA reductase inhibitor with lipid-lowering activity that can reduce low-density lipoprotein cholesterol levels. Cerivastatin sodium has anticancer effects and can be used to study primary hyperlipidemia. |
| In vitro | Cerivastatin sodium 5-50 ng/mL treatment induces a dose-dependent decrease in cell proliferation of MDA-MB-231 cells (up to 40% inhibition at 25 ng/mL), and 10-25 ng/mL Cerivastatin sodium inhibits invasion of MDA-MB-231 cells through Matrigel. [1] 25 ng/mL Cerivastatin sodium delocalizes RhoA and Ras from the membrane to the cytosol and induces morphological changes, and induces a marked increase in the level of p21Waf1/Cip1. This treatment increases the p21 transcript in MDA-MB-231 cells, and induces inactivation of NFκB, in a RhoA inhibition-dependent manner, resulting in a decrease in urokinase and metalloproteinase-9 expression, and concomitantly increases IκB. [1] |
| In vivo | Cerivastatin sodium is well absorbed, reaching maximum plasma concentrations within 1-3 hours after oral administration. In the circulation, it is highly bound to plasma proteins (99.5%) and has an elimination half-life of 2-4 h. Cerivastatin sodium is metabolized primarily by the liver to three polar metabolites. Two of these metabolites are somewhat active, but much less so than the prodrug, while the third metabolite is inactive. Plasma concentrations of these metabolites are much lower than those of the prodrug. The metabolites are excreted primarily in the urine (20-25%) and feces (66-73%), with little detectable excretion of the unchanged prodrug. [2] |
| Storage | store at low temperature,keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 80 mg/mL (166.14 mM.), Sonication is recommended. DMSO : 80 mg/mL (166.14 mM), Sonication is recommended. |
| Keywords | OpioidReceptor | Opioid Receptor | NOP receptor | HMGCoAReductase | HMG-CoA reductase | HMG-CoA Reductase | HMGCoA Reductase | Ferroptosis | Cerivastatin sodium |
| Inhibitors Related | TBHQ | Rosiglitazone | α-Vitamin E | L-Glutamic acid | Sorafenib | Curcumin | Gallic Acid Monohydrate | Artemisinin | L-Cystine | L-Glutamine | L-Glutamic acid monosodium salt | Cisplatin |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $457.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-06-17 | |
| $350.00/1KG |
VIP6Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2020-07-13 | |
| $138.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2025-05-02 | |
| $0.00/1KG |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-05-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY